<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "5: uncertainties", fill: "#f88379"},
{source: "5: uncertainties", target: "5: unexpected technical", fill: "#f88379"},
{source: "5: unexpected technical", target: "5: marketing difficulties inherent", fill: "#f88379"},
{source: "5: marketing difficulties inherent", target: "5: product development efforts such as", fill: "#f88379"},
{source: "5: product development efforts such as", target: "5: new applications", fill: "#f88379"},
{source: "5: new applications", target: "5: longterm strategy", fill: "#f88379"},
{source: "5: longterm strategy", target: "5: future developments", fill: "#f88379"},
{source: "5: future developments", target: "5: future advances", fill: "#f88379"},
{source: "5: future advances", target: "5: diagnostic testing", fill: "#f88379"},
{source: "5: diagnostic testing", target: "5: procedures as well", fill: "#f88379"},
{source: "5: procedures as well", target: "5: government regulations", fill: "#f88379"},
{source: "5: government regulations", target: "5: healthcare policies both", fill: "#f88379"},
{source: "5: healthcare policies both", target: "5: which could adversely affect", fill: "#f88379"},
{source: "5: which could adversely affect", target: "5: procedures automated by", fill: "#f88379"},
{source: "5: procedures automated by", target: "5: increasing competition from imaging", fill: "#f88379"},
{source: "5: increasing competition from imaging", target: "5: diagnostic products", fill: "#f88379"},
{source: "5: uncertainties", target: "6: additional significant uncertainties", fill: "#808080"},
{source: "6: additional significant uncertainties", target: "12: Failure ", fill: "#ef98aa"},
{source: "12: Failure ", target: "12: significant", fill: "#ef98aa"},
{source: "12: significant", target: "12: successfully", fill: "#ef98aa"},
{source: "12: successfully", target: "12: marketing strategy will", fill: "#ef98aa"},
{source: "12: marketing strategy will", target: "12: financial condition", fill: "#ef98aa"},
{source: "12: financial condition", target: "12: operations", fill: "#ef98aa"},
{source: "12: Failure ", target: "18: market will accept", fill: "#fff600"},
{source: "18: market will accept", target: "18: future products", fill: "#fff600"},
{source: "18: future products", target: "18: systems will grow at", fill: "#fff600"},
{source: "18: systems will grow at", target: "18: management", fill: "#fff600"},
{source: "18: market will accept", target: "23: technology", fill: "#321414"},
{source: "23: technology", target: "23: compete successfully with", fill: "#321414"},
{source: "23: compete successfully with", target: "23: competitors", fill: "#321414"},
{source: "23: technology", target: "29: commercial success depends", fill: "#c19a6b"},
{source: "29: commercial success depends", target: "29: Automated Intelligent Microscopy or AIM ", fill: "#c19a6b"},
{source: "29: Automated Intelligent Microscopy or AIM ", target: "29: proprietary technology", fill: "#c19a6b"},
{source: "29: commercial success depends", target: "32: Therefore ", fill: "#e0b0ff"},
{source: "32: Therefore ", target: "32: under patents currently", fill: "#e0b0ff"},
{source: "32: under patents currently", target: "32: future patent applications will", fill: "#e0b0ff"},
{source: "32: future patent applications will", target: "32: sufficiently broad", fill: "#e0b0ff"},
{source: "32: sufficiently broad", target: "32: adequately", fill: "#e0b0ff"},
{source: "32: adequately", target: "32: proprietary rights", fill: "#e0b0ff"},
{source: "32: Therefore ", target: "START_HERE", fill: "#e0b0ff"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Electronic Equipment and Instruments</td>
    </tr>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Provide shelter</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Propose</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
    <tr>
      <td>Natural disaster</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Travel to meet</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Product_lifecycle">Product lifecycle</a></td>
      <td>In industry, Product Lifecycle Management (PLM) is the process of managing the entire lifecycle of a product from its inception through the engineering, design and manufacture, as well as the service and disposal of manufactured products. PLM integrates people, data, processes and business systems and provides a product information backbone for companies and their extended enterprises.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competition">Competition</a></td>
      <td>Competition is a rivalry where two or more parties strive for a common goal which cannot be shared: where one's gain is the other's loss (an example of which is a zero-sum game). Competition can arise between entities such as organisms, individuals, economic and social groups, etc.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_figures">Significant figures</a></td>
      <td>Significant figures (also known as the significant digits, precision or resolution) of a number in positional notation are digits in the number that are reliable and necessary to indicate the quantity of something.\nIf a number expressing the result of a measurement (e.g., length, pressure, volume, or mass) has more digits than the number of digits allowed by the measurement resolution, then only as many digits as allowed by the measurement resolution are reliable, and so only these can be significant figures.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Simpsons">The Simpsons</a></td>
      <td>The Simpsons is an American animated sitcom created by Matt Groening for the Fox Broadcasting Company. The series is a satirical depiction of American life, epitomized by the Simpson family, which consists of Homer, Marge, Bart, Lisa, and Maggie.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Internet">Internet</a></td>
      <td>In finance and economics, interest is payment from a borrower or deposit-taking financial institution to a lender or depositor of an amount above repayment of the principal sum (that is, the amount borrowed), at a particular rate. It is distinct from a fee which the borrower may pay the lender or some third party.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_condition_report">Financial condition report</a></td>
      <td>In accounting, a financial condition report (FCR) is a report on the solvency condition of an insurance company that takes into account both the current financial status, as reflected in the balance sheet, and an assessment of the ability of the company to survive future risk scenarios. Risk assessment in an FCR involves dynamic solvency testing, a type of dynamic financial analysis that simulates management response to risk scenarios, to test whether a company could remain solvent in the face of deteriorating economic conditions or major disasters.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Balance_sheet">Balance sheet</a></td>
      <td>In financial accounting, a balance sheet (also known as statement of financial position or statement of financial condition) is a summary of the financial balances of an individual or organization, whether it be a sole proprietorship, a business partnership, a corporation, private limited company or other organization such as government or not-for-profit entity. Assets, liabilities and ownership equity are listed as of a specific date, such as the end of its financial year.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_ratio">Financial ratio</a></td>
      <td>A financial ratio or accounting ratio is a relative magnitude of two selected numerical values taken from an enterprise's financial statements. Often used in accounting, there are many standard ratios used to try to evaluate the overall financial condition of a corporation or other organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_law">Financial law</a></td>
      <td>Financial law is the law and regulation of the insurance, derivatives, commercial banking, capital markets and investment management sectors. Understanding Financial law is crucial to appreciating the creation and formation of banking and financial regulation, as well as the legal framework for finance generally.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Trustmark_(bank)">Trustmark (bank)</a></td>
      <td>Trustmark is a commercial bank and financial services company headquartered in Jackson, Mississippi, United States, with subsidiaries Trustmark National Bank, Trustmark Investment Advisors, and Fisher Brown Bottrell Insurance. The bank's initial predecessor, The Jackson Bank, was chartered by the State of Mississippi in 1889.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_analysis">Financial analysis</a></td>
      <td>Financial analysis (also referred to as financial statement analysis or accounting analysis or Analysis of finance) refers to an assessment of the viability, stability, and profitability of a business, sub-business or project. \nIt is performed by professionals who prepare reports using ratios and other techniques, that make use of information taken from financial statements and other reports.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Federal_takeover_of_Fannie_Mae_and_Freddie_Mac">Federal takeover of Fannie Mae and Freddie Mac</a></td>
      <td>In September 2008 the Federal Housing Finance Agency (FHFA) announced that it would take over the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac). Both government-sponsored enterprises, which finance home mortgages in the United States by issuing bonds, had become illiquid as the market for those bonds collapsed in the subprime mortgage crisis.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_operations">Special operations</a></td>
      <td>Special operations (S.O.) are military activities conducted, according to NATO, by "specially designated, organized, selected, trained, and equipped forces using unconventional techniques and modes of employment". Special operations may include reconnaissance, unconventional warfare, and counter-terrorism actions, and are typically conducted by small groups of highly-trained personnel, emphasizing sufficiency, stealth, speed, and tactical coordination, commonly known as "special forces".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Management">Management</a></td>
      <td>Management (or managing) is the administration of an organization, whether it is a business, a non-profit organization, or a government body. It is the art and science of managing resources of the business.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Agile_management">Agile management</a></td>
      <td>Agile management is the application of the principles of Agile software development to various management processes, particularly project management. Following the appearance of the Manifesto for Agile Software Development in 2001, Agile techniques started to spread into other areas of activity.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Network_management">Network management</a></td>
      <td>Network management is the process of administering and managing computer networks. Services provided by this discipline include fault analysis, performance management, provisioning of networks and maintaining quality of service.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Risk_management">Risk management</a></td>
      <td>Risk management is the identification, evaluation, and prioritization of risks (defined in ISO 31000 as the effect of uncertainty on objectives) followed by coordinated and economical application of resources to minimize, monitor, and control the probability or impact of unfortunate events or to maximize the realization of opportunities.\nRisks can come from various sources including uncertainty in international markets, threats from project failures (at any phase in design, development, production, or sustaining of life-cycles), legal liabilities, credit risk, accidents, natural causes and disasters, deliberate attack from an adversary, or events of uncertain or unpredictable root-cause.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Women_Management">Women Management</a></td>
      <td>Women Management is a modeling agency based in New York. Founded by Paul Rowland in 1988,  Women also has two sister agencies, Supreme Management and Women 360 Management, which is also part of the Women International Agency Chain.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_management">Emergency management</a></td>
      <td>Emergency management, also called emergency response or disaster management, is the organization and management of the resources and responsibilities for dealing with all humanitarian aspects of emergencies (prevention, preparedness, response, mitigation, and recovery). The aim is to prevent and reduce the harmful effects of all hazards, including disasters.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sport_management">Sport management</a></td>
      <td>Sport management is the field of business dealing with sports and recreation. Sports management involves any combination of skills that correspond with planning, organizing, directing, controlling, budgeting, leading, or evaluating of any organization or business within the sports field.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Test_management">Test management</a></td>
      <td>Test management most commonly refers to the activity of managing a testing process. A test management tool is software used to manage tests (automated or manual) that have been previously specified by a test procedure.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitor_analysis">Competitor analysis</a></td>
      <td>Competitive analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors. This analysis provides both an offensive and defensive strategic context to identify opportunities and threats.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitor_backlinking">Competitor backlinking</a></td>
      <td>Competitor backlinking is a search engine optimization strategy that involves analyzing the backlinks of competing websites within a vertical search. The outcome of this activity is designed to increase organic search engine rankings and to gain an understanding of the link building strategies used by business competitors.By analyzing the backlinks to competitor websites, it is possible to gain a benchmark on the number of links and the quality of links that is required for high search engine rankings.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitors_for_the_Crown_of_Scotland">Competitors for the Crown of Scotland</a></td>
      <td>When the crown of Scotland became vacant in September 1290 on the death of the seven-year-old child Queen Margaret, 13 claimants to the throne came forward. Those with the most credible claims were John Balliol, Robert Bruce, John Hastings and Floris V, Count of Holland.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sport_of_athletics">Sport of athletics</a></td>
      <td>Athletics is a group of sporting events that involves competitive running, jumping, throwing, and walking. The most common types of athletics competitions are track and field, road running, cross country running, and racewalking.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_Dancing_with_the_Stars_(American_TV_series)_competitors">List of Dancing with the Stars (American TV series) competitors</a></td>
      <td>Dancing with the Stars is an American reality television show in which celebrity contestants and professional dance partners compete to be the best dancers, as determined by the show's judges and public voting. The series first broadcast in 2005, and thirty complete seasons have aired on ABC. During each season, competitors are progressively eliminated on the basis of public voting and scores received from the judges until only a few contestants remain.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitor_Group">Competitor Group</a></td>
      <td>Competitor Group, Inc. (CGI) is a privately held, for-profit, sports marketing and management company based in Mira Mesa, San Diego, California.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Proprietary_software">Proprietary software</a></td>
      <td>Proprietary software, also known as non-free software or closed-source software, is computer software for which the software's publisher or another person reserves some licensing rights to use, modify, share modifications, or share the software, restricting user freedom with the software they lease. It is the opposite of open-source or free software.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Proprietary_firmware">Proprietary firmware</a></td>
      <td>Proprietary firmware is any firmware on which is not free (libre). Examples of proprietary works include ones upon which the author has placed restrictions on use, private modification, copying, or republishing.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>IRIS INTERNATIONAL INC      Item 1A Risk <font color="blue">Factors     </font>     Forward-Looking Statements          This <font color="blue">Annual Report </font>on Form 10-K contains forward-looking statements, which     reflect our current views <font color="blue">about future events</font> and financial results</td>
    </tr>
    <tr>
      <td>We have     made these statements in <font color="blue">reliance on</font> the <font color="blue">safe harbor</font> created by that Private     Securities Litigation Reform Act of 1995</td>
    </tr>
    <tr>
      <td>Forward-looking statements include     our  views  on  future  financial  results, financing sources, product     development, capital <font color="blue">requirements</font>, market growth and the like, and are     <font color="blue">generally</font>  identified  by  phrases  such as “anticipates,” “believes,”     “estimates,”   “expects,”   “intends,”   “plans”  and  similar  words</td>
    </tr>
    <tr>
      <td>Forward-looking statements are <font color="blue">merely predictions</font> and therefore inherently     subject to <font color="blue">uncertainties</font> and other <font color="blue">factors which could</font> cause the actual     results to <font color="blue">differ materially from</font> the forward-looking statement</td>
    </tr>
    <tr>
      <td>These <font color="blue">uncertainties</font> and other factors include, among other things:           •   <font color="blue">unexpected technical</font> and <font color="blue">marketing <font color="blue">difficult</font>ies inherent</font> in major     <font color="blue">product development efforts such as</font> the <font color="blue">new applications</font> for our urinalysis     workstation,           •   the potential need for changes in our long-term strategy in response     to <font color="blue">future developments</font>,           •   <font color="blue">future advances</font> in <font color="blue">diagnostic testing</font> methods and procedures, as well     as potential changes in <font color="blue"><font color="blue"><font color="blue">government</font> regulation</font>s</font> and healthcare policies, both     of <font color="blue">which <font color="blue">could <font color="blue">adversely affect</font></font></font> the economics of the <font color="blue">diagnostic testing</font>     <font color="blue">procedures automated by</font> our products,           •   <font color="blue">increasing <font color="blue">competition</font> from imaging</font> and non-imaging based in-vitro     <font color="blue">diagnostic products</font></td>
    </tr>
    <tr>
      <td>Set forth below are additional <font color="blue">significant</font> <font color="blue">uncertainties</font> and other factors     affecting forward-looking statements</td>
    </tr>
    <tr>
      <td>The <font color="blue">readers should</font> understand that the     <font color="blue">uncertainties</font> and other factors identified in this <font color="blue">Annual Report </font>are not a     <font color="blue">comprehensive list</font> of all the <font color="blue">uncertainties</font> and other factors that may     affect forward-looking statements</td>
    </tr>
    <tr>
      <td>We do not undertake any <font color="blue">obligation</font> to     update or revise any forward-looking statements or the list of <font color="blue">uncertainties</font>     and other factors that <font color="blue">could affect</font> those statements</td>
    </tr>
    <tr>
      <td>Related to Our Business          Our <font color="blue"><font color="blue">success depends</font> largely on</font> the <font color="blue">acceptance</font> of our iQ200 product line</td>
    </tr>
    <tr>
      <td>Our <font color="blue">current strategy</font> assumes that our iQ200 operating <font color="blue">platform will</font> be     <font color="blue">adopted by</font> a large number of end-users</td>
    </tr>
    <tr>
      <td>We have invested and continue to     invest a substantial amount of our resources in promotion and marketing of     the iQ200 product line in order to increase its market <font color="blue">penetration</font>, expand     <font color="blue">sales into new geographic areas</font> and enhance and expand its system features</td>
    </tr>
    <tr>
      <td><font color="blue">Failure  </font>of  our  iQ200  operating  platform to achieve and maintain a     <font color="blue">significant</font> market presence, or the failure to <font color="blue">successfully</font> implement our     promotion and marketing strategy, will have a material adverse effect on our     <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Any failure to <font color="blue">successfully</font> introduce our <font color="blue"><font color="blue">future product</font>s</font> and <font color="blue">systems into</font>     the <font color="blue">market <font color="blue">could <font color="blue">adversely affect</font></font></font> our business</td>
    </tr>
    <tr>
      <td>The <font color="blue">commercial success</font> of our <font color="blue"><font color="blue">future product</font>s</font> and <font color="blue">systems depends upon</font> their     <font color="blue">acceptance</font>  by the <font color="blue">medical community</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">future product</font> plans include     capital-intensive <font color="blue">laboratory <font color="blue">instruments</font></font></td>
    </tr>
    <tr>
      <td>We believe that these products can     <font color="blue">significant</font>ly  reduce  labor  costs, improve precision and offer other     <font color="blue">distinctive benefits</font> to the <font color="blue">medical research community</font></td>
    </tr>
    <tr>
      <td>However, there is     often  market  resistance to products that require <font color="blue">significant</font> capital     <font color="blue">expenditures</font>  or  which  <font color="blue">eliminate jobs through automation</font></td>
    </tr>
    <tr>
      <td>We have no     assurance that the <font color="blue">market will accept</font> our <font color="blue"><font color="blue">future product</font>s</font> and systems, or     that sale of our <font color="blue"><font color="blue">future product</font>s</font> and <font color="blue">systems will grow at</font> the rates expected     by our <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>Any failure to <font color="blue">successfully</font> develop <font color="blue"><font color="blue">new products</font> <font color="blue">could <font color="blue">adversely affect</font></font></font> our     business</td>
    </tr>
    <tr>
      <td>Our <font color="blue">commercial success</font> depends on the <font color="blue">timely development</font> of <font color="blue">new products</font>     that are needed for <font color="blue">future growth</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">new products</font> depend on our success     in  <font color="blue">demonstrating technical feasibility</font> and achieving <font color="blue">cost targets</font> and     <font color="blue">functionality demanded by</font> the market</td>
    </tr>
    <tr>
      <td><font color="blue">Significant </font>delays in <font color="blue">product releases</font>     will result in budget over-runs and <font color="blue">lower revenues</font></td>
    </tr>
    <tr>
      <td>10     ______________________________________________________________________    [38]Table of <font color="blue">Contents       </font>If we fail to meet changing demands of <font color="blue">technology</font>, we may not continue to be     able to compete <font color="blue">successfully</font> with our <font color="blue"><font color="blue">competitor</font>s</font></td>
    </tr>
    <tr>
      <td>The  market  for  our  products  and systems is <font color="blue">characterized by rapid</font>     <font color="blue">technological advances</font>, changes in <font color="blue">customer <font color="blue">requirements</font></font>, and <font color="blue">frequent new</font>     <font color="blue">product <font color="blue">introduction</font>s</font> and <font color="blue">enhancements</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">future <font color="blue">success depends</font> upon</font> our     ability  to  introduce  <font color="blue">new products</font> that keep <font color="blue">pace with technological</font>     developments, enhance current product lines and respond to <font color="blue">evolving customer</font>     <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>Our failure to meet these <font color="blue">demands could</font> result in a loss of     our market share and <font color="blue">competitiveness</font> and <font color="blue">could harm</font> our revenues and results     of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Any  failure  or  <font color="blue">inability</font> to protect our <font color="blue">technology</font> and <font color="blue">confidential</font>     information <font color="blue">could <font color="blue">adversely affect</font></font> our business</td>
    </tr>
    <tr>
      <td>Our <font color="blue">commercial success</font> depends in part on our ability to protect     and  maintain  our Automated Intelligent Microscopy (or AIM) and other     <font color="blue">proprietary</font> <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>We have received <font color="blue">patents with respect</font> to portions of     the <font color="blue">technologies</font> of AIM However, ownership of <font color="blue">technology</font> patents may not     insulate  us  <font color="blue">from potentially damaging <font color="blue">competition</font></font></td>
    </tr>
    <tr>
      <td>Patent <font color="blue">litigation</font>     relating to <font color="blue">clinical laboratory instrumentation patents</font> (like the ones we     own) <font color="blue">often involves complex legal</font> and factual questions</td>
    </tr>
    <tr>
      <td>Therefore, we can     make no assurance that claims <font color="blue">under patents currently</font> held by us, or our     pending  or  future patent applications, will be <font color="blue">sufficiently broad</font> to     <font color="blue">adequately</font>  protect  what  we  believe  to  be our <font color="blue"><font color="blue">proprietary</font> rights</font></td>
    </tr>
    <tr>
      <td>Additionally,  one  or  more of our <font color="blue">patents could</font> be <font color="blue">circumvented by</font> a     <font color="blue">competitor</font></td>
    </tr>
    <tr>
      <td>We believe that our <font color="blue"><font color="blue">proprietary</font> rights</font> do not <font color="blue">infringe upon</font> the     <font color="blue"><font color="blue">proprietary</font> rights</font> of <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>However, <font color="blue">third parties</font> may assert     <font color="blue">infringement</font> claims <font color="blue">against us</font> in the future</td>
    </tr>
    <tr>
      <td>If we are <font color="blue">unsuccessful</font> in our     <font color="blue">defense against</font> any <font color="blue">infringement</font> claim our patents, or patents in which we     have licensed rights, may be held invalid and unenforceable</td>
    </tr>
    <tr>
      <td><font color="blue">Trade Secrets</font></td>
    </tr>
    <tr>
      <td>We have trade secrets, unpatented <font color="blue">technology</font> and <font color="blue">proprietary</font>     knowledge  related  to the sale, promotion, operation, development and     <font color="blue">manufacturing</font> of our products</td>
    </tr>
    <tr>
      <td>We <font color="blue">generally</font> enter into <font color="blue">confidential</font>ity     <font color="blue"><font color="blue">agreement</font>s with</font> our employees, suppliers and <font color="blue">consultants</font></td>
    </tr>
    <tr>
      <td>However, we cannot     guarantee that our trade secrets, unpatented <font color="blue">technology</font> or <font color="blue">proprietary</font>     knowledge  will  not  become  known  or  be <font color="blue">independently</font> developed by     <font color="blue"><font color="blue">competitor</font>s</font></td>
    </tr>
    <tr>
      <td>If any of this <font color="blue">proprietary</font> information <font color="blue">becomes known</font> to third     parties, we may have <font color="blue">no practical recourse against</font> these parties</td>
    </tr>
    <tr>
      <td><font color="blue">Copyrights and Trademarks</font></td>
    </tr>
    <tr>
      <td>We claim <font color="blue">copyrights</font> in our software and the ways     in which it assembles and <font color="blue">displays images</font></td>
    </tr>
    <tr>
      <td>We also claim <font color="blue">trademark rights</font> in     the <font color="blue">United States </font>and other <font color="blue">foreign countries</font></td>
    </tr>
    <tr>
      <td>However, we can make no     assurance that we will be able to obtain <font color="blue">enforceable copyright</font> and trademark     protection,  nor  that  this  <font color="blue">protection will provide us</font> a <font color="blue">significant</font>     <font color="blue">commercial advantage</font></td>
    </tr>
    <tr>
      <td><font color="blue">Potential Litigation Expenses</font></td>
    </tr>
    <tr>
      <td><font color="blue">Offensive </font>or <font color="blue">defensive</font> <font color="blue">litigation</font> regarding     patent and other <font color="blue"><font color="blue"><font color="blue">intellectual</font> property rights</font> could</font> be time-consuming and     expensive</td>
    </tr>
    <tr>
      <td>Additionally, <font color="blue">litigation</font> could demand <font color="blue">significant</font> attention from     our technical and <font color="blue">management</font> personnel</td>
    </tr>
    <tr>
      <td>Any change in our ability to protect     and maintain our <font color="blue"><font color="blue">proprietary</font> rights</font> could materially and <font color="blue">adversely affect</font>     our <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">products could</font> infringe on</font> the <font color="blue"><font color="blue">intellectual</font> property rights</font> of others</td>
    </tr>
    <tr>
      <td>Given the complete factual and legal issues associated with <font color="blue">intellectual</font>     property rights, there can be no assurance that our current and future     products do not or will not infringe the <font color="blue"><font color="blue">intellectual</font> property rights</font> of     others</td>
    </tr>
    <tr>
      <td>A <font color="blue">determination</font> that such <font color="blue">infringement</font> exists or even a claim that     it exists <font color="blue">could involve us</font> in costly <font color="blue">litigation</font> and have an adverse effect     on our business and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>We operate in a <font color="blue">consolidating industry</font> that creates barriers to our market     <font color="blue">penetration</font></td>
    </tr>
    <tr>
      <td>The  healthcare  industry  in  recent  years has <font color="blue">been characterized by</font>     <font color="blue">consolidation</font></td>
    </tr>
    <tr>
      <td>Large <font color="blue">hospital chains</font> and groups of <font color="blue">affiliated hospitals</font>     prefer to <font color="blue">negotiate comprehensive supply contracts</font> for all of their supply     needs at                                           11     ______________________________________________________________________    [39]Table of <font color="blue">Contents       </font>once</td>
    </tr>
    <tr>
      <td>Large  suppliers can <font color="blue">often equip</font> an <font color="blue">entire laboratory</font> and offer     <font color="blue">hospital chains</font> and groups one-stop shopping for <font color="blue">laboratory <font color="blue">instruments</font></font>,     supplies and service</td>
    </tr>
    <tr>
      <td>Larger suppliers also typically offer annual rebates     to their <font color="blue">customers based on</font> the customer’s total volume of business with the     supplier</td>
    </tr>
    <tr>
      <td>The convenience and <font color="blue">rebates offered by</font> these large suppliers are     <font color="blue">administrative</font> and <font color="blue">financial incentives</font> that we do not offer our customers</td>
    </tr>
    <tr>
      <td>Our plans for further market <font color="blue">penetration</font> in the <font color="blue">urinalysis market will</font>     depend  in  part on our ability to overcome these and any <font color="blue">new barriers</font>     resulting from continued <font color="blue">consolidation</font> in the <font color="blue">healthcare industry</font></td>
    </tr>
    <tr>
      <td>The     failure to <font color="blue">overcome such barriers could</font> have a material adverse effect on     our <font color="blue">financial condition</font> or results of operation</td>
    </tr>
    <tr>
      <td>Since  we operate in the medical <font color="blue">technology</font> industry, our products are     subject to <font color="blue"><font color="blue">government</font> regulation</font> that <font color="blue">could impair</font> our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Most of our products are subject to stringent <font color="blue"><font color="blue">government</font> regulation</font> in the     United  States  and other countries</td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">regulatory</font> processes</font> can be     lengthy,  expensive  and  uncertain</td>
    </tr>
    <tr>
      <td>Additionally, <font color="blue">securing <font color="blue">necessary</font></font>     <font color="blue">clearances</font> or <font color="blue">approvals may</font> require the submission of extensive official     data and other supporting information</td>
    </tr>
    <tr>
      <td>Our failure to <font color="blue"><font color="blue">comply with</font> applicable</font>     <font color="blue">requirements</font> could result in fines, recall or seizure of products, total or     <font color="blue">partial suspension</font> of production, withdrawal of <font color="blue">existing product approvals</font>     or <font color="blue">clearances</font>, refusal to approve or clear <font color="blue">new applications</font> or notices, or     <font color="blue">criminal prosecution</font></td>
    </tr>
    <tr>
      <td>If any of these events were to occur, they <font color="blue">could harm</font>     our  business</td>
    </tr>
    <tr>
      <td><font color="blue">Changes  </font>in existing federal, state or <font color="blue">foreign laws</font> or     <font color="blue">regulations</font>, or in the <font color="blue">interpretation</font> or <font color="blue">enforcement</font> of these laws, could     <font color="blue">also materially</font> and <font color="blue">adversely affect</font> our business</td>
    </tr>
    <tr>
      <td>Changes in <font color="blue"><font color="blue">government</font> regulation</font> of the <font color="blue">healthcare industry</font> could adversely     affect our business</td>
    </tr>
    <tr>
      <td>Federal and state <font color="blue">legislative</font> proposals are <font color="blue">periodically</font> introduced or     proposed  that  would  affect  major changes in the <font color="blue">healthcare system</font>,     nationally, at the state level or both</td>
    </tr>
    <tr>
      <td>Future <font color="blue">legislation</font>, regulation or     <font color="blue">payment policies</font> of Medicare, Medicaid, <font color="blue">private health insurance</font> plans,     health  maintenance  <font color="blue">organizations</font>  and other third-party payors could     <font color="blue">adversely affect</font> the demand for our current or <font color="blue"><font color="blue">future product</font>s</font> and our     ability to sell our <font color="blue">products on</font> a <font color="blue">profitable basis</font></td>
    </tr>
    <tr>
      <td>Moreover, healthcare     <font color="blue">legislation</font>  is an area of extensive and dynamic change, and we cannot     predict future <font color="blue">legislative</font> changes in the <font color="blue">healthcare field</font> or their impact     on our industry or our business</td>
    </tr>
    <tr>
      <td>Any <font color="blue">impairment</font> in our ability to market our     <font color="blue">products could</font> have a material adverse effect on our <font color="blue">financial condition</font> and     results of operation</td>
    </tr>
    <tr>
      <td>We may not be able to realize the <font color="blue">deferred tax asset</font> relating to our tax net     operating loss carry forward</td>
    </tr>
    <tr>
      <td><font color="blue">As of December </font>31, 2005, we have <font color="blue">deferred tax asset</font>s of approximately dlra10     million resulting from the <font color="blue">differences</font> between the <font color="blue">financial statement</font> and     the tax bases of assets and <font color="blue">liabilities using enacted tax rates</font> in effect     for the year in which the <font color="blue">differences</font> are expected to reverse</td>
    </tr>
    <tr>
      <td><font color="blue">Management     </font>believes it is more <font color="blue">likely than</font> not that the <font color="blue">deferred tax asset</font>s will be     realized  <font color="blue">through future taxable income</font> or <font color="blue">alternative tax strategies</font></td>
    </tr>
    <tr>
      <td>However, the net <font color="blue">deferred tax asset</font>s could be reduced in the near term if     <font color="blue">management</font>’s estimates of <font color="blue">taxable income during</font> the <font color="blue">carryforward period</font> are     not realized or are <font color="blue">significant</font>ly reduced or <font color="blue">alternative tax strategies</font> are     not available</td>
    </tr>
    <tr>
      <td><font color="blue">Although the Company </font>believes that the <font color="blue">deferred tax asset</font> is     recoverable, there is no assurance that we will be able to <font color="blue">generate taxable</font>     income in the years that the <font color="blue">differences</font> reverse</td>
    </tr>
    <tr>
      <td>Also, if we undergo an     ownership change as defined in Section 382 of the Internal Revenue Code,     NOLs <font color="blue">generated prior</font> to the ownership change would be subject to an annual     <font color="blue">limitation</font></td>
    </tr>
    <tr>
      <td>If this occurs, a <font color="blue">valuation allowance may</font> be <font color="blue">necessary</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">rely on independent</font> and some single-source suppliers for <font color="blue">key <font color="blue">components</font></font>     of our <font color="blue">instruments</font></td>
    </tr>
    <tr>
      <td>Any delay or <font color="blue">disruption</font> in the supply of <font color="blue"><font color="blue">components</font> may</font>     <font color="blue">prevent us from selling</font> our products and <font color="blue">negatively impact</font> our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Certain of our <font color="blue">components</font> are obtained from outside vendors, and the loss or     <font color="blue">breakdown</font> of our <font color="blue"><font color="blue">relationship</font>s with</font> these <font color="blue">outside vendors could</font> subject us     to substantial delays in the delivery of our products to our customers</td>
    </tr>
    <tr>
      <td><font color="blue">Furthermore </font>certain <font color="blue">key <font color="blue">components</font></font> of our <font color="blue">instruments</font> are <font color="blue"><font color="blue">manufacture</font>d by</font>     <font color="blue">only one supplier</font></td>
    </tr>
    <tr>
      <td>12     ______________________________________________________________________    [40]Table of <font color="blue">Contents       </font>For example, ARKRAY is the <font color="blue">single source supplier</font> for our line of urine     <font color="blue">chemistry analyzers</font> and related <font color="blue">consumable products</font> and <font color="blue">spare parts</font></td>
    </tr>
    <tr>
      <td>Roche     Diagnostics is the sole source for our <font color="blue">proprietary</font> CHEMSTRIP/IRIStrip urine     <font color="blue">test strips</font> and related <font color="blue">urine test strip</font> readers, both used in our legacy     <font color="blue">instruments</font>, the Model 500 and 939UDx urinalysis workstations</td>
    </tr>
    <tr>
      <td>Because these     suppliers are the <font color="blue">only vendors with which</font> we have a <font color="blue">relationship</font> for a     particular component, we may be unable to <font color="blue">sell products</font> if one of these     <font color="blue">suppliers becomes unwilling</font> or unable to deliver <font color="blue">components</font> meeting our     <font color="blue">specifications</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">inability</font> to <font color="blue">sell products</font> to <font color="blue">meet delivery schedules</font>     could have a material adverse effect on our reputation in the industry, as     well as our <font color="blue">financial condition</font> and results of operation</td>
    </tr>
    <tr>
      <td>One of our single-source suppliers has terminated its <font color="blue">agreement</font> with us</td>
    </tr>
    <tr>
      <td><font color="blue">Roche Diagnostics </font>has exercised its right to terminate its <font color="blue"><font color="blue">agreement</font>s with</font>     us  relating to the supply of <font color="blue">test strips</font> and related <font color="blue">urine test strip</font>     readers</td>
    </tr>
    <tr>
      <td>Roche <font color="blue">will continue</font> to supply <font color="blue">test strips</font> and <font color="blue">replacement readers</font>     to our <font color="blue">installed base</font> of legacy workstations until 2009</td>
    </tr>
    <tr>
      <td>The failure to     <font color="blue">successfully</font> and timely complete the <font color="blue">phase out</font> of their strips and readers     with the <font color="blue">introduction</font> of our new iQ200 analyzers would have a material     <font color="blue">adverse affect on</font> our instrument sales and the <font color="blue">revenue growth</font> for system     <font color="blue">consumables</font> and service</td>
    </tr>
    <tr>
      <td>We  face  intense  <font color="blue">competition</font> and our failure to <font color="blue">compete <font color="blue">effective</font>ly</font>,     <font color="blue">particularly against larger</font>, more <font color="blue">established companies will</font> cause our     business to suffer</td>
    </tr>
    <tr>
      <td>The <font color="blue">healthcare industry</font> is <font color="blue">highly competitive</font></td>
    </tr>
    <tr>
      <td>We compete in this industry     based primarily on product performance, service and price</td>
    </tr>
    <tr>
      <td>Many of our     <font color="blue"><font color="blue">competitor</font>s</font>  have <font color="blue">substantially</font> greater financial, technical and human     resources than we do, and may also have <font color="blue">substantially</font> greater experience in     developing products, obtaining <font color="blue">regulatory</font> approvals and <font color="blue">manufacturing</font> and     marketing and <font color="blue">distribution</font></td>
    </tr>
    <tr>
      <td>Further, our <font color="blue">competitive position could</font> be <font color="blue">harmed by</font> the <font color="blue">establishment</font> of     patent  <font color="blue">protection by</font> our <font color="blue"><font color="blue">competitor</font>s</font> or other companies</td>
    </tr>
    <tr>
      <td>The existing     <font color="blue"><font color="blue">competitor</font>s</font> or other <font color="blue">companies may</font> succeed in developing <font color="blue">technologies</font> and     products that are more <font color="blue">effective</font> or <font color="blue">affordable than</font> those being developed by     us or that would render our <font color="blue">technology</font> and <font color="blue">products less competitive</font> or     obsolete</td>
    </tr>
    <tr>
      <td>If  we are unable to <font color="blue">effective</font>ly compete in our market, our     <font color="blue">financial condition</font> and results of <font color="blue">operation will materially suffer</font></td>
    </tr>
    <tr>
      <td>Our  success  depends  on  our ability to attract, retain and motivate     <font color="blue">management</font> and other <font color="blue">skilled employees</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">success depends</font> in <font color="blue">significant</font> part upon the <font color="blue">continued services</font> of key     <font color="blue">management</font> and <font color="blue">skilled personnel</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>for qualified personnel is     intense and there are a limited number of people with knowledge of, and     experience in, our industry</td>
    </tr>
    <tr>
      <td>We do not have employment <font color="blue"><font color="blue">agreement</font>s with</font> most     of our <font color="blue">key employees nor</font> maintain <font color="blue">life insurance polices on them</font></td>
    </tr>
    <tr>
      <td>The loss     of key personnel, especially without advance notice, or our <font color="blue">inability</font> to     hire or retain qualified personnel, could have a material adverse effect on     our instrument sales and our ability to maintain our <font color="blue">technological edge</font></td>
    </tr>
    <tr>
      <td>We     <font color="blue">cannot guarantee</font> that we <font color="blue">will continue</font> to retain our key <font color="blue">management</font> and     <font color="blue">skilled personnel</font>, or that we will be able to attract, assimilate and retain     other <font color="blue">highly qualified personnel</font> in the future</td>
    </tr>
    <tr>
      <td><font color="blue">Defective </font><font color="blue">products may</font> subject us to <font color="blue">liability</font></td>
    </tr>
    <tr>
      <td>Our  products are used to gather information for <font color="blue">medical decisions</font> and     <font color="blue">diagnosis</font></td>
    </tr>
    <tr>
      <td>Accordingly,  a defect in the design or <font color="blue">manufacture</font> of our     products,  or a failure of our products to perform for the use that we     specify, could have a material adverse effect on our reputation in the     industry and subject us to claims of <font color="blue">liability</font> arising <font color="blue">from <font color="blue">inaccurate</font></font> or     <font color="blue"><font color="blue">allegedly</font> <font color="blue">inaccurate</font> test</font> results</td>
    </tr>
    <tr>
      <td>Misuse of our products by a technician     that  results in <font color="blue">inaccurate</font> or <font color="blue"><font color="blue">allegedly</font> <font color="blue">inaccurate</font> test</font> results could     similarly subject us to claims of <font color="blue">liability</font></td>
    </tr>
    <tr>
      <td>We currently maintain product     <font color="blue">liability</font> insurance coverage for up to dlra1dtta0 million per incident and up to     an aggregate of dlra2dtta0 million per year</td>
    </tr>
    <tr>
      <td>We <font color="blue">also currently</font> maintain a product     <font color="blue">liability</font> umbrella policy for coverage of claims                                           13     ______________________________________________________________________    [41]Table of <font color="blue">Contents       </font><font color="blue">aggregating</font> to dlra10dtta0 million</td>
    </tr>
    <tr>
      <td>Although <font color="blue">management</font> believes this <font color="blue">liability</font>     coverage is <font color="blue">sufficient protection against future</font> claims, there can be no     assurance of the <font color="blue">sufficiency</font> of these policies</td>
    </tr>
    <tr>
      <td>Any substantial <font color="blue">underinsured</font>     loss would have a material adverse effect on our <font color="blue">financial condition</font> and     results of operation</td>
    </tr>
    <tr>
      <td>Furthermore, any <font color="blue">impairment</font> of our reputation could     have  a  material adverse effect on our sales and prospects for future     business</td>
    </tr>
    <tr>
      <td>We have not received any <font color="blue">indication</font> that our <font color="blue">insurance carrier</font>     will not renew our product <font color="blue">liability</font> insurance at or near <font color="blue">current premiums</font>;     however, we <font color="blue">cannot guarantee</font> that this <font color="blue">will continue</font> to be the case</td>
    </tr>
    <tr>
      <td>In     addition, any failure to <font color="blue">comply with</font> <font color="blue">Federal Drug Administration </font><font color="blue">regulations</font>     governing <font color="blue">manufacturing</font> practices could hamper our ability to <font color="blue">defend against</font>     product <font color="blue">liability</font> lawsuits</td>
    </tr>
    <tr>
      <td>Business <font color="blue">interruption</font>s <font color="blue">could <font color="blue">adversely affect</font></font> our business</td>
    </tr>
    <tr>
      <td><font color="blue">Products for Iris Diagnostics and Sample Processing </font>are <font color="blue">manufacture</font>d in a     <font color="blue">single facility</font> for each division and are vulnerable to <font color="blue">interruption</font> in the     event  of  war,  terrorism,  fire,  earthquake,  power  loss,  floods,     <font color="blue">telecommunications failure</font> and other <font color="blue">events beyond</font> our control</td>
    </tr>
    <tr>
      <td>If our     <font color="blue">facilities</font> were <font color="blue">significant</font>ly damaged or <font color="blue">destroyed by</font> any cause, we would     experience delays in locating a <font color="blue">new facility</font> and equipment and qualifying     the <font color="blue">new facility</font> with the FDA Our results <font color="blue">would suffer</font></td>
    </tr>
    <tr>
      <td>In addition, we may     not carry adequate business <font color="blue">interruption</font> insurance to <font color="blue">compensate us</font> for     losses that may occur and any losses or <font color="blue">damages incurred by us could</font> be     substantial</td>
    </tr>
    <tr>
      <td>If we are unable to manage our growth, our results <font color="blue">could suffer</font></td>
    </tr>
    <tr>
      <td>We have been experiencing <font color="blue">significant</font> growth in the scope of our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>This growth has placed <font color="blue">significant</font> demands on our <font color="blue">management</font>, as well as     <font color="blue">operational resources</font></td>
    </tr>
    <tr>
      <td>In order to achieve our business <font color="blue">objectives</font>, we     anticipate that we will need to continue to grow</td>
    </tr>
    <tr>
      <td>If this growth occurs, it     <font color="blue">will continue</font> to place additional <font color="blue">significant</font> demands on our <font color="blue">management</font> and     our <font color="blue">operational resources</font>, and will require that we continue to develop and     improve our operational, financial and other <font color="blue">internal controls both</font> in the     US and <font color="blue"><font color="blue">international</font>ly</font></td>
    </tr>
    <tr>
      <td>In particular, if our <font color="blue">growth continues</font>, it will     increase  the  <font color="blue">challenges</font> in <font color="blue">implementing appropriate control systems</font>,     expanding our sales and marketing infrastructure capabilities, providing     <font color="blue">adequate training</font> and <font color="blue">supervision</font> to maintain <font color="blue">high quality standards</font>, and     preserving our <font color="blue">cultural values</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">main challenge associated with</font> our     growth has been the <font color="blue">management</font> of our expenses</td>
    </tr>
    <tr>
      <td>Our <font color="blue">inability</font> to scale our     business  <font color="blue">appropriately</font>  or <font color="blue">otherwise adapt</font> to growth, could cause our     business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font> to suffer</td>
    </tr>
    <tr>
      <td>Our <font color="blue">quarterly sales</font> and operating results <font color="blue">may fluctuate</font> in <font color="blue">future periods</font>,     and  if we fail to <font color="blue">meet <font color="blue">expectations</font></font> the price of our <font color="blue"><font color="blue">common stock</font> may</font>     decline</td>
    </tr>
    <tr>
      <td>Our <font color="blue">quarterly sales</font> and operating results have fluctuated <font color="blue">significant</font>ly in     the past and are likely to do so in the future due to a number of factors,     many  of  which  are not within our control</td>
    </tr>
    <tr>
      <td>If our <font color="blue">quarterly sales</font> or     operating results fall below the <font color="blue">expectations</font> of investors or securities     analysts, the price of our <font color="blue">common stock</font> could decline <font color="blue">substantially</font></td>
    </tr>
    <tr>
      <td><font color="blue">Factors     </font>that might cause <font color="blue">quarterly <font color="blue">fluctuation</font>s</font> in our sales and operating results     include the following:           •   variation in demand for our products, including <font color="blue">seasonality</font>;           •   our ability to develop, introduce, market and gain market <font color="blue">acceptance</font>     of <font color="blue">new products</font> and product <font color="blue">enhancements</font> in a <font color="blue">timely manner</font>;           •   our ability to manage inventories, accounts receivable and <font color="blue">cash flows</font>;           •   our ability to <font color="blue">control costs</font>;           •   the size, timing, rescheduling or <font color="blue">cancellation</font> of <font color="blue">orders from</font>     consumers and <font color="blue"><font color="blue">distributor</font>s</font>; and           •   our ability to <font color="blue">forecast <font color="blue">future sales</font></font> and operating results and     <font color="blue">subsequently attain them</font></td>
    </tr>
    <tr>
      <td>The  amount of expenses we <font color="blue">incur depends</font>, in part, on our <font color="blue">expectations</font>     regarding <font color="blue">future sales</font></td>
    </tr>
    <tr>
      <td>In particular, we expect to <font color="blue">continue incurring</font>     substantial  expenses  relating  to the marketing and promotion of our     products</td>
    </tr>
    <tr>
      <td>14     ______________________________________________________________________    [42]Table of <font color="blue">Contents       </font>Since many of our costs are fixed in the short term, if we have a shortfall     in  sales, we may be unable to <font color="blue">reduce expenses quickly enough</font> to avoid     losses</td>
    </tr>
    <tr>
      <td>Accordingly, you should     not rely on quarter-to-quarter comparisons of our operating results as an     <font color="blue">indication</font> of our <font color="blue">future performance</font></td>
    </tr>
    <tr>
      <td>We depend on independent <font color="blue"><font color="blue">distributor</font>s</font> to sell our products in <font color="blue">international</font>     markets</td>
    </tr>
    <tr>
      <td>We  sell  our  products  in  <font color="blue">international</font> markets through independent     <font color="blue"><font color="blue">distributor</font>s</font></td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">distributor</font>s</font> may not command the <font color="blue">necessary</font> resources to     <font color="blue">effective</font>ly market and sell our products</td>
    </tr>
    <tr>
      <td>If a <font color="blue">distributor</font> fails to meet     annual sales goals, it may be <font color="blue">difficult</font> and costly to locate an acceptable     substitute <font color="blue">distributor</font></td>
    </tr>
    <tr>
      <td>If a change in our <font color="blue"><font color="blue">distributor</font>s</font> becomes <font color="blue">necessary</font>,     we may experience <font color="blue">increased costs</font>, as well as substantial <font color="blue">disruption</font> and a     resulting loss of sales</td>
    </tr>
    <tr>
      <td>Our sales in <font color="blue">international</font> markets are subject to a variety of laws and     political and <font color="blue">economic risks</font> that <font color="blue">may adversely impact</font> our sales and results     of <font color="blue">operations</font> in <font color="blue">certain regions</font></td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">capitalize on growth</font> in <font color="blue">international</font> markets is subject to     risks including:           •   changes in <font color="blue">currency exchange rates which impact</font> the price to     <font color="blue">international</font> consumers;           •   the burdens of <font color="blue">complying with</font> a variety of <font color="blue">foreign laws</font> and     <font color="blue">regulations</font>;           •   unexpected changes in <font color="blue">regulatory</font> <font color="blue">requirements</font>; and           •   the <font color="blue">difficult</font>ies associated with promoting products in unfamiliar     cultures</td>
    </tr>
    <tr>
      <td>We are also subject to general, political, economic and <font color="blue">regulatory</font> risks in     <font color="blue">connection with</font> our <font color="blue">international</font> sales <font color="blue">operations</font>, including:           •   <font color="blue">political instability</font>;           •   changes in diplomatic and trade <font color="blue">relationship</font>s;           •   <font color="blue">general economic <font color="blue">fluctuation</font>s</font> in <font color="blue">specific countries</font> or markets; and           •   changes in <font color="blue">regulatory</font> schemes</td>
    </tr>
    <tr>
      <td>Any of the above mentioned factors <font color="blue">could <font color="blue">adversely affect</font></font> our sales and     results of <font color="blue">operations</font> in <font color="blue">international</font> markets</td>
    </tr>
    <tr>
      <td>We are subject to <font color="blue">currency <font color="blue">fluctuation</font>s</font></td>
    </tr>
    <tr>
      <td>We are exposed to <font color="blue">certain foreign currency risks</font> in the <font color="blue">importation</font> of goods     from Japan</td>
    </tr>
    <tr>
      <td>The line of urine <font color="blue">chemistry analyzers</font>, two assemblies for our     iQ200 platform and related <font color="blue">consumables</font> strips and <font color="blue">spare parts</font> are sourced     from ARKRAY, a supplier located in Kyoto, Japan</td>
    </tr>
    <tr>
      <td>Our <font color="blue">purchases from</font> this     supplier are <font color="blue">denominated</font> in <font color="blue">Japanese Yen</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">components</font> represent a     <font color="blue">significant</font> portion of our material costs</td>
    </tr>
    <tr>
      <td>Fluctuations in the US Dollar/     <font color="blue">Japanese Yen</font> <font color="blue">exchange rate could</font> result in <font color="blue">increased costs</font> for our key     <font color="blue">components</font></td>
    </tr>
    <tr>
      <td>Any increases would reduce our gross margins and would be likely     to result in a material adverse effect on our <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Similarly, we     are <font color="blue">also exposed</font> to <font color="blue">currency <font color="blue">fluctuation</font>s</font> with respect to the <font color="blue">exportation</font> of     our products</td>
    </tr>
    <tr>
      <td>All of our sales are <font color="blue">denominated</font> <font color="blue">in US Dollars</font></td>
    </tr>
    <tr>
      <td>Accordingly,     any <font color="blue">fluctuation</font> in the <font color="blue">exchange rate between</font> the US Dollar and the currency     of the <font color="blue">country with which</font> we are exporting <font color="blue">products could</font> also affect our     ability to sell <font color="blue"><font color="blue">international</font>ly</font></td>
    </tr>
    <tr>
      <td>Risks Related to Ownership of Our Common Stock          Anti-takeover  provisions  of  <font color="blue">Delaware  </font><font color="blue">law could delay</font> or prevent an     <font color="blue">acquisition</font> of our Company</td>
    </tr>
    <tr>
      <td>We  are  subject to the anti-takeover provisions of Section 203 of the     Delaware General Corporation Law, which regulates corporate <font color="blue">acquisition</font>s</td>
    </tr>
    <tr>
      <td>These provisions could discourage potential <font color="blue">acquisition</font> proposals and could     delay or prevent a change in <font color="blue">control transaction</font></td>
    </tr>
    <tr>
      <td>They <font color="blue">could also</font> have the     effect of <font color="blue">discouraging others from</font> making <font color="blue">tender offers</font> for our <font color="blue">common stock</font>     or preventing changes in our <font color="blue">management</font></td>
    </tr>
  </tbody>
</table>